Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba
Article content
ZUG, Switzerland — Galderma Group AG (SWX:GALD):
Article content
Article content
Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH ('EQT'), Abu Dhabi Investment Authority ('ADIA') and Auba Investment Pte. Ltd. ('Auba') announced today
The repurchased shares will be held in treasury and financed by existing liquidity at hand
Article content
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering ('ABO') of approximately 16.7 million Galderma shares (approximately 7% of Galderma's share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding.
Article content
The repurchased shares will be financed by Galderma's existing liquidity on hand and will not affect the company's ability to deliver on its strategic and financing priorities.
Article content
The shares will be held in treasury for future use in connection with Galderma's employee participation plans, business development opportunities and/or treasury management.
Article content
About Galderma
Article content
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
Article content
Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as 'plans', 'targets', 'aims', ' believes', 'expects', 'anticipates', 'intends', 'estimates', 'will', 'may', 'continues', 'should' and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma's markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.
Article content
Article content
Article content
Article content
Contacts
Article content
For further information:
Article content
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Article content
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Article content
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's 'Retinal Vein Occlusion Pipeline Insight 2025' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It covers the Retinal Vein Occlusion pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Retinal Vein Occlusion pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Retinal Vein Occlusion Pipeline. Dive into DelveInsight's comprehensive report today! @ Retinal Vein Occlusion Pipeline Outlook Key Takeaways from the Retinal Vein Occlusion Pipeline Report In May 2025, Bayer conducted a study treatment intravitreal (IVT) aflibercept is given as an injection into the eye. It works by blocking VEGF and this can help repair vision problems related to RVO. IVT aflibercept is already available and is prescribed by doctors as the standard of care treatment for macula edema secondary to RVO. Standard of care is a treatment that medical experts consider most appropriate for a disease. In May 2025, EyeBiotech Ltd announced a Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD). DelveInsight's Retinal Vein Occlusion Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Retinal Vein Occlusion treatment. The leading Retinal Vein Occlusion Companies such as Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Promising Retinal Vein Occlusion Pipeline Therapies such as Ranibizumab, RFB002, Dexamethasone, pegaptanib sodium, AKB-9778, Aflibercept, Bevacizumab and others. Stay ahead with the most recent pipeline outlook for Retinal Vein Occlusion Treatment. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Retinal Vein Occlusion Treatment Drugs Retinal Vein Occlusion Emerging Drugs Profile KSI-301: Kodiak sciences The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen. 601: Sunshine Guojian Pharmaceutical 601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials. IBE-814: Ripple Therapeutics IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO). The Retinal Vein Occlusion Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Retinal Vein Occlusion with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion Treatment. Retinal Vein Occlusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Retinal Vein Occlusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinal Vein Occlusion Market Explore groundbreaking therapies and clinical trials in the Retinal Vein Occlusion Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Retinal Vein Occlusion Drugs Retinal Vein Occlusion Companies Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravitreal Subretinal Topical. Molecule Type Retinal Vein Occlusion Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Retinal Vein Occlusion Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Retinal Vein Occlusion Market Drivers and Barriers Scope of the Retinal Vein Occlusion Pipeline Report Coverage- Global Retinal Vein Occlusion Companies- Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Retinal Vein Occlusion Pipeline Therapies- Ranibizumab, RFB002, Dexamethasone, pegaptanib sodium, AKB-9778, Aflibercept, Bevacizumab and others. Retinal Vein Occlusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Retinal Vein Occlusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Retinal Vein Occlusion Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Retinal Vein Occlusion Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Retinal Vein Occlusion: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) KSI-301: Kodiak sciences Drug profiles in the detailed report….. Mid Stage Products (Phase II) 601: Sunshine Guojian Pharmaceutical Drug profiles in the detailed report….. Early Stage Products (Phase I) MHU650: Novartis Drug profiles in the detailed report….. Inactive Products Retinal Vein Occlusion Key Companies Retinal Vein Occlusion Key Products Retinal Vein Occlusion- Unmet Needs Retinal Vein Occlusion- Market Drivers and Barriers Retinal Vein Occlusion- Future Perspectives and Conclusion Retinal Vein Occlusion Analyst Views Retinal Vein Occlusion Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
3 hours ago
- Globe and Mail
ChargePoint (CHPT) Q1 2026 Earnings Transcript
DATE Wednesday, June 4, 2025 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Rick Wilmer Chief Financial Officer — Mansi Khetani Need a quote from one of our analysts? Email pr@ TAKEAWAYS Total Revenue: $98 million for Q1 FY2026, in line with company guidance. Non-GAAP Gross Margin: 31%, a non-GAAP improvement of one percentage point sequentially and seven percentage points year over year (non-GAAP). SaaS Subscription Gross Margin: Achieved a record 60% on a GAAP basis. Adjusted EBITDA Loss: $23 million non-GAAP adjusted EBITDA loss, compared with a $17 million loss in the prior quarter and a $36 million loss in the first quarter of last year. Network Charging Systems Revenue: $52 million, representing 53% of total revenue, almost flat sequentially despite Q1 typically experiencing a seasonal dip and down 20% year on year. Subscription Revenue: $38 million in subscription revenue, or 39% of total revenue, essentially flat sequentially and up 14% year on year. Other Revenue: $8 million, or 8% of total revenue, down 31% sequentially and down 8% year on year, mainly due to lower one-time project revenue. Geographic Mix: North America represented 85% of revenue, and Europe was 15%, with European revenue down mainly due to weakness in Germany. Billings Mix by Vertical: Commercial 71%, fleet 13%, residential 12%, and other 3%. Inventory: Inventory balance increased by $3 million due to FX impacts, but inventory units decreased across most products as sell-through continued. Ending Cash Balance: $196 million in cash on hand, with access to a $150 million undrawn revolving credit facility. Charging Ports Under Management: Over 352,000 total under management, including more than 35,000 DC fast chargers and over 122,000 ports in Europe. Roaming Partnerships: Enabled access to more than 1.25 million charging ports globally. New Product Announcements: Introduction of a theft-resistant charging cable and a new AC hardware architecture, with the latter targeting lower cost and improved margins. Eaton Partnership: Announced collaboration with Eaton to deliver integrated EV charging and power management solutions, with initial co-developed products set for announcement in September. Q2 Revenue Guidance: Expected revenue in the range of $90 million to $100 million. Operational Focus: Continued emphasis on gross margin expansion, cost management, and achieving adjusted EBITDA positivity in a quarter during FY2026. SUMMARY ChargePoint Holdings, Inc. (NYSE:CHPT) reported first-quarter revenue that matched internal expectations, highlighting stable top-line performance despite ongoing macroeconomic and policy headwinds. Management stated that new integrated solutions from the Eaton partnership are now available for order, and further product innovations are scheduled for announcement in September, aiming to bolster incremental revenue growth and differentiation. The company confirmed that new AC hardware will launch at a competitive price to support both US and European expansion, with rollout of the new architecture planned over the next year and the first model targeted for production in July. Wilmer said, "We still expect non-GAAP margin improvement later in FY2026." emphasizing that anticipated US tariffs will have only a minimal cost impact due to effective mitigation actions. Management highlighted US and European EV sales grew 16% and 22%, respectively, in Q1, positioning infrastructure utilization as a positive demand signal for future industry expansion. Wilmer stated that voluntary industry exits and increased regulatory scrutiny on competitors create "a meaningful opportunity for ChargePoint Holdings, Inc. to gain market share." Khetani remarked that "inventory balance will reduce gradually throughout the year, helping to free up cash." A more significant decrease is anticipated in the second half as revenue increases. INDUSTRY GLOSSARY CPO: Charge Point Operator, an entity responsible for managing and maintaining EV charging infrastructure. V2X: Vehicle-to-Everything, a technology enabling electric vehicles to exchange power or information with the grid, buildings, and other systems. AC Hardware Architecture: Alternating Current charging system design, indicating the product and platform structure for AC chargers as opposed to Direct Current (DC) fast chargers. ATM: At-the-Market offering, a program allowing companies to sell shares into the open market over time. Full Conference Call Transcript Rick Wilmer: Good afternoon, and welcome to ChargePoint Holdings, Inc.'s first quarter fiscal 2026 earnings call. Today, I will walk you through key results for the quarter, provide insights into recent market and policy developments, and highlight the progress we have made on our two major priorities for the year: delivering innovation and driving growth. In addition, I will cover two significant announcements that directly support these priorities and positively influence ChargePoint Holdings, Inc.'s path to achieving positive non-GAAP adjusted EBITDA in a quarter of this fiscal year. Let's begin with our Q1 financial results. Revenue for the first quarter came in at $98 million, right within our guidance range. Non-GAAP gross margin continues to increase quarter over quarter, reaching a new high of 31%. Notably, our SaaS subscription gross margin climbed to a record 60%, underscoring the strength of our SaaS-focused business model. We built momentum across the business in Q1. Our DC fast charging program with General Motors has been a success, with the pace of site openings accelerating and over 500 additional ports signed off by GM for deployment. We extended multiple agreements with Mercedes-Benz, reinforcing our long-term relationship. Our theft-resistant charging cable was met with strong market interest and will go into production this summer for our own hardware models. Deenergized, our software management solution for CPOs, is now actively managing over 700 charger models from over 85 different vendors of charging hardware. This is a testimonial to the scale of our third-party hardware integrations. In total, ChargePoint Holdings, Inc. now has over 352,000 ports under management, of which more than 35,000 are DC fast chargers, and more than 122,000 are located in Europe. With our roaming partnerships, we enable access to more than 1.25 million charging ports globally. Our business is proving to be resilient on the top line despite US macroeconomic conditions and market uncertainty, as well as the bottom line through the cost and operational actions we took last year. Looking ahead regarding US tariffs on our products, expect only a minimal increase in the cost of goods sold. Also, expect cost reductions to exceed the impact of the current tariffs. Therefore, we still expect margin improvement later in the year. The limited impact reflects the swift and effective execution of our mitigation plan. We see positive momentum on two fronts: one, EV adoption, and two, utilization rates. EV adoption continues on a steady upward trajectory, a trend which has held for more than a year. Despite political turbulence dampening consumer and capital spending, North American EV sales were up 16% year over year for Q1 according to Rimotion. In Europe, EV momentum rebounded strongly with the same data set reporting 22% EV sales growth year over year for Q1, a significant surge. The European Green Deal mandates all new cars sold there be zero emission by 2035, reinforcing the EU's trajectory of EV adoption. All of this forms a strong leading indicator for the charging industry. The trends we observed last quarter remain intact. The market is actively planning and inquiring, but widespread purchasing is being impacted by economic uncertainty. Inevitably, with more EVs on the road, existing infrastructure is under mounting pressure. A recent report by Perin Data concluded that many US cities are approaching maximum charge utilization during peak hours, with five major markets past or approaching a staggering 40% utilization rate. This strain is a positive signal for our customers who monetize charging, but it is a growing concern for EV drivers facing long waits at occupied stations. We believe this will lead to the installation of more chargers, and ChargePoint Holdings, Inc. will be ready to capitalize on that demand. Despite the growth to come, the market has recently seen attrition and the voluntary exit of major players, even Chinese competitors coming under the scrutiny of the federal government. These developments, while natural for a new industry at our stage, create a meaningful opportunity for ChargePoint Holdings, Inc. to gain market share. We are not waiting for the growth to come to us; we are actively pursuing it. This brings me to the most exciting announcement of the year so far: our new partnership with Eaton, one of the world's largest intelligent power management companies. The cornerstone of this partnership is innovation, which will drive growth. Our goal is to make electrified transportation simple and economically a no-brainer. Charging deployments are increasingly complex, with a significant portion of them requiring grid upgrades. So we are integrating charging and electrical equipment into a single solution which addresses a major gap in the market. Together, ChargePoint Holdings, Inc. and Eaton will deliver EV charging, electrical infrastructure, energy management, and engineering services as the market's only end-to-end EV charging and power management solutions. These fully integrated solutions will get our customers up and running faster, simultaneously lowering their costs, and are available for order now. The next phase of the partnership will offer co-developed future technologies to further drive down costs, improve efficiency, and advance bidirectional power flow technology to fully optimize V2X capabilities. This will enable customers to use EVs as another distributed energy resource they can integrate into their energy infrastructure to help power operations. The first innovations from this effort are set to be announced in September. So what does this do for ChargePoint Holdings, Inc.'s business? In addition to a compelling and highly differentiated offering, we now have access to Eaton's formidable go-to-market engine, which does nearly $25 billion in annual sales across more than 160 countries. We anticipate that the relationship will drive incremental revenue growth for ChargePoint Holdings, Inc. This partnership cements ChargePoint Holdings, Inc. as the enabler of the entire EV ecosystem, from the grid to the dashboard of the vehicle and everything in between. Our second major announcement of the quarter, once again aligned with our goal of delivering innovation, was the announcement of our new AC hardware architecture. This is the first product line developed utilizing our lower-cost co-development structure and will enter the market at a highly competitive price point while still increasing our margins. This new architecture underpins a range of upcoming models that will roll out over the next year, serving home, commercial, and fleet use cases. These products will represent a major portion of our hardware volume. By bringing a generational leap in our technology to market at an affordable price point, we anticipate greater volume in the US, where we have the number one AC market share and considerable market penetration in Europe, where we have not had a product in this category to date. The first charger, part of our European take-home fleet solution, is expected to begin production in July. Growth and innovation remain the year two priorities of our strategic plan, and we are making progress on both. We entered year two ahead of schedule, positioning us to realize the benefits of our streamlined cost structure and revitalized product portfolio in year three. Our partnership with Eaton unlocks immediate growth opportunities by combining our EV charging leadership with their complementary solutions and their commercial scale. Our new AC hardware architecture is the first of several high-impact innovations planned for this year, designed to expand market share, drive volume, and improve margins. Combined with our operational excellence, we are laying the groundwork for meaningful financial upside as the year moves on. I will now turn the call over to our CFO, Mansi Khetani, to cover our financials in more detail. Mansi Khetani: Thanks, Rick. As a reminder, please see our earnings press release where we reconcile our non-GAAP results to GAAP. Our principal exclusions are stock-based compensation, amortization of intangible assets, and certain costs related to restructuring and acquisitions. Revenue for the first quarter was $98 million, within our guidance range. Network charging systems at $52 million accounted for 53% of first-quarter revenue. This was almost flat sequentially despite Q1 typically experiencing a seasonal dip and was down 20% year on year. Subscription revenue at $38 million was 39% of total revenue, essentially flat sequentially mostly due to fewer days in Q1 which impacts prorated revenue recognition, and up 14% year on year due to the recurring revenue generated from a higher installed base. Other revenue at $8 million was 8% of total revenue, down 31% sequentially and down 8% year on year. Other includes various revenue items which tend to be lumpy and was significantly lower this quarter primarily as a result of lower one-time project revenue which is recognized based on completion rate. Turning to verticals, which we report from a billing perspective, first-quarter billings percentages were commercial 71%, fleet 13%, residential 12%, and other 3%. From a geographic perspective, North America made up 85% of revenue, and Europe was 15%. Europe was lower than normal, due largely to weakness in Germany. This was partially made up in North America, which was slightly higher compared to last quarter even though the first quarter is typically seasonally lower and despite significant macroeconomic headwinds. Non-GAAP gross margin was 31%, improving by one percentage point sequentially and up seven percentage points year on year. This is attributable to higher margins in both hardware and subscription, as well as subscription revenue growing as a percentage of total revenue. Hardware gross margin increased sequentially despite the impact of incremental tariffs and freight incurred in Q1. Subscription margins reached a record high of 60% on a GAAP basis and were even higher on a non-GAAP basis due to economies of scale and continued optimization of support costs. Based on currently available information, we expect the financial impact of tariffs on our COGS to remain minimal and expect gross margins to continue around the current range and to further improve later in the year. Non-GAAP operating expenses were $57 million, up 9% sequentially and down 15% year on year. As mentioned previously, this quarter's OpEx included the impact of annual raises and investments in certain key areas of the business. We will continue to manage OpEx closely. Non-GAAP adjusted EBITDA loss was $23 million. This compared with a loss of $17 million in the prior quarter and a loss of $36 million in the first quarter of last year. Stock-based compensation was $18 million, up from $15 million in the prior quarter and down from $22 million year on year. Our inventory balance increased by $3 million due to the impact of foreign exchange rates on inventory held by our international subsidiaries. However, we saw a decrease in inventory units across most products as we continue to sell through. We anticipate that inventory balance will reduce gradually throughout the year, helping to free up cash. Speaking of cash, we ended the quarter with $196 million in cash on hand. Q1 tends to be the quarter with the highest cash usage due to the timing of some large annual payments. We will continue to rigorously manage cash, and we have access to a $150 million revolving credit facility which remains undrawn. We have no debt maturities until 2028, and we have existing capacity on our ATM. Turning to guidance, for the second quarter of fiscal 2026, we expect revenue to be $90 million to $100 million. We are guiding with caution due to the continued changes in the macro environment, including tariff uncertainty, as well as our near-term focus on operationalizing our partnership with Eaton. While there is always a possibility of headwinds from deterioration in macro conditions, we expect revenue upside later in the year from the introduction of our new AC hardware that Rick outlined, better performance in Europe, and growth from our new partnership with Eaton. We continue to focus on revenue growth, gross margin expansion, and cost management to achieve our stated goal of being adjusted EBITDA positive in a quarter during fiscal 2026. We will now open the call for questions. At this time, I would like to remind everyone, in order to ask a question, please press star then the number one on your telephone keypad. We request that you limit yourself to one question and one follow-up. We will pause for just a moment to compile the Q&A roster. Our first question comes from the line of Colin Rusch with Oppenheimer. Your line is open. Colin Rusch: Thanks so much, guys. You know, with this Eaton partnership and what you are seeing in terms of the market and the new AC product, can you talk a little bit about the pipeline of activity and how we should be thinking about a return to growth here on the top line for the new systems? Rick Wilmer: Yeah. Thanks, Colin. I think there are a variety of forces at play, some positive, some causing caution. Obviously, the macroeconomic conditions, tariffs, and we are seeing some customers get conservative with spending in cash. There is obviously uncertainty around policies supporting the electrification of transportation, particularly in the US, which I think are also headwinds. On the other hand, we are very excited about our partnership with Eaton. We fully expect that to drive incremental growth, and there is a lot of work to do this quarter in particular to operationalize this relationship. We fully expect to hit our stride and have this, again, fully operationalized as we enter our fiscal Q3. So a variety of factors at play. Colin Rusch: Okay. And then in terms of international expansion, you know, ex-Europe, is Eaton able to help you guys get into some incremental geographies where you have not been operating to date? And how should we think about the potential for the opportunity in Central South America, other parts of North America where you are not maybe fully loaded? You know, it seems like you have got pretty good coverage in the US and Canada, but maybe you are missing something. And then, you know, potentially places like Australia and others where you could see some incremental sales. Rick Wilmer: Yeah. Eaton definitely has the capabilities to do that. At this point in time, we are focused on North America and Europe. We believe with the combined product portfolio, what we have to offer in Europe and North America, we have got plenty of TAM to address in those two geographies. But, again, the possibility definitely exists to penetrate new partnership. Colin Rusch: Thanks so much. And then just a final one on the cadence of the inventory reduction, Mansi. Should we be thinking about that as kind of low single-digit millions, mid-single-digit millions, of inventory consumption on a quarterly basis? Just want to get a better sense of how to get that number on a trajectory basis and what is the right target for you guys in terms of the right inventory that you want to be carrying on an ongoing basis? Mansi Khetani: Yeah. So, you know, obviously, there are a lot of factors that inventory balance will depend on. It depends on the mix of sell-through, the mix of production, etc. So all we can say right now is that we expect gradual reduction with a more meaningful reduction coming in the second half as we see revenue growth. Colin Rusch: Okay. I will hop back in queue. Thanks, guys. Operator: Thank you. Again, if you would like to ask a question, press star one on your telephone keypad. That is all the questions for today. Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 994%* — a market-crushing outperformance compared to 172% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of June 2, 2025 This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Globe and Mail
3 hours ago
- Globe and Mail
Global Ophthalmic Implants Market Revenue to Reach USD 8.14 billion by 2030 – Exclusive Research by Focus Reports
"Global Ophthalmic Implants Market Revenue to Reach USD 8.14 billion by 2030 - Exclusive Research by Focus Reports" Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025–2030. According to Focus Report's latest research report, the global ophthalmic implants market is growing at a CAGR of 7.48% during 2021-2030. Looking for More Information? Click: Report Scope: Market Size (2030): USD 8.14 Billion Market Size (2024): USD 5.28 Billion CAGR (2024-2030): 7.48% Historic Year: 2021-2023 Base Year: 2024 Forecast Year: 2025-2030 Largest Region (2024): North America Fastest-Growing Region: Asia Pacific Market Segmentation: Product, Application, End-Users, and Geography Geographic Analysis: North America, Europe, APAC, Latin America, and the Middle East & Africa Market Overview The global ophthalmic implants market is evolving rapidly, driven by the increasing burden of eye diseases, a growing ageing population, and rising healthcare expenditure dedicated to vision care. Eye health continues to be a critical global concern, with leading organizations such as the World Health Organization (WHO), the International Agency for the Prevention of Blindness (IAPB), and the American Academy of Ophthalmology, along with numerous regional and national health authorities, playing an active role in promoting eye care awareness and access to surgical interventions. The COVID-19 pandemic significantly disrupted the ophthalmology landscape, resulting in widespread delays and cancellations of elective eye surgeries and consultations. This disruption led to a notable slowdown in the ophthalmic implants market between 2019 and 2020, with a substantial decline in surgical volumes and overall market revenues. However, easing restrictions in 2021 led to a surge in postponed procedures, boosting demand for ophthalmic implants. After a slight dip in 2022 as backlogs cleared, the market has stabilized since 2023 and is expected to maintain consistent growth supported by ongoing innovations and rising patient awareness. Growing Adoption of Synthetic Corneal Implants Expands Treatment Options for High-Risk Patients The growing use of synthetic corneal implants is bringing new hope to patients suffering from corneal blindness, especially those who cannot undergo traditional corneal transplants. While donor cornea transplants work well for many, they often fail in patients with conditions like chronic inflammation, glaucoma, herpes infections, or excessive blood vessel growth in the cornea. In addition, the global demand for donor corneas far exceeds supply, particularly in developing countries. Synthetic corneal implants, known as keratoprostheses, offer an effective alternative. According to the Cornea Research Foundation of America (2025), these fully artificial implants are now widely available and are helping restore vision in patients who are not suitable for human donor transplants. With an estimated 11 million people worldwide affected by bilateral corneal blindness (2022), this advancement is making treatment more accessible, reducing wait times, and improving outcomes for those most in need. By offering a reliable solution where traditional methods fall short, synthetic implants are enhancing care and quality of life for patients around the world. Rising Adoption of Advanced Ocular Devices Opens New Horizons in Eye Care Market The eye implant market is witnessing significant momentum, driven by the rising acceptance of advanced ocular technologies such as artificial eyes and glaucoma management devices. This growing adoption is being further supported by a surge in regulatory approvals, enabling leading manufacturers to expand their product portfolios and capitalize on new revenue streams. Ongoing investments in R&D are paving the way for next-generation eye care solutions, with cutting-edge ophthalmic diagnostics accelerating clinical acceptance and market penetration. Increased digital accessibility has also played a crucial role in patient education, empowering individuals to explore innovative treatment options and thereby boosting demand. One notable advancement gaining traction is the artificial corneal implant, which has emerged as a crucial alternative for patients unsuitable for human donor transplants. As highlighted by the Cornea Research Foundation of America (2023), while over 11 million people globally suffer from corneal blindness, only 100,000 receive donor-based implants, underscoring a critical gap and reinforcing the need for synthetic alternatives. The European Blind Union (2022) reports that nearly 30 million people in Europe are affected by visual impairments, driving the need for more frequent and sophisticated corneal procedures. With an aging population and rising expectations for high-quality eye care, the adoption of advanced ocular implants is expected to accelerate in the years ahead. Recent Vendor Activities In 2024, Alimera Sciences was acquired by ANI Pharmaceuticals to expand its footprint into the ophthalmology sector. This transaction is valued at around $381 million. Alimera Sciences was offered 2 ophthalmic implants that treat posterior eye diseases. In 2024, Johnson & Johnson Medtech- one of the global companies in eye health launched TECNIS PureSee (Intraocular Lens) to correct refractive presbyopia in Europe and the Middle East and Africa (EMEA). In 2024, Occular Therapeutix, a biopharmaceutical company, announced that the first patients had been enrolled in the phase 3 SOL-R clinical studies evaluating repeat dosing of the AXPAXLI implant for the treatment of a patient with wet AMD. Strategic Innovations and Collaborations Drive Expansion in Ophthalmic Implants Market In recent years, the global ophthalmic implants industry has experienced dynamic strategic activities, including mergers, acquisitions, and partnerships, aimed at expanding global footprints and accelerating product innovation. Leading companies such as Alcon, ZEISS Group, Bausch + Lomb, and Johnson & Johnson continue to dominate the market, offering advanced ophthalmic implant solutions that not only fulfill consumer needs but also adhere to stringent regulatory standards. These key players are enhancing product efficiency and solidifying their market positions through robust brand presence and extensive geographic reach worldwide. The competitive landscape has intensified as vendors increasingly deploy strategies like new product launches, strategic mergers and acquisitions, and the integration of cutting-edge technologies and materials into their offerings. A notable example includes Science Corporation's acquisition of Pixium's PRIMA Retinal Implants, marking a significant step in their commitment to vision restoration. While this innovative retinal implant is not yet commercially available, promising preliminary clinical trial results highlight the potential of emerging technologies to revolutionize ocular care and expand market opportunities. Key Vendors Alcon Carl Zeiss Bausch + Lomb Johnson & Johnson Other Prominent Vendors AJL Ophthalmic BVI Care Group CorNeat Vision Devine Meditech EyeD Pharma Ani Pharmaceuticals Eyedeal Medical Technology Company Limited Müller Söhne Gulden Ophthalmics Glaukos HumanOptics Hoya Corporation LambdaVision Labtician Ophthalmics MORCHER iSTAR Medical Ophtec Omni Lens Rayner Intraocular Lenses Limited SMR OPHTHALMIC Ocular Therapeutix F. Hoffmann-La Roche Market Segmentation & Forecast Product Intraocular Lenses Glaucoma Implants Corneal Implants Others Application Cataract Surgery Glaucoma Surgery Other Applications End-Users Hospitals Ophthalmic Clinics Other End-User Geography North America US Canada Europe Germany UK France Italy Spain APAC China Japan India Australia South Korea Latin America Brazil Mexico Argentina Middle East & Africa Turkey Saudi Arabia South Africa Other Related Reports that Might be of Your Business Requirement Global Contact Lenses Market - Focused Insights 2024-2029 Global Disposable Contact Lenses Market - Focused Insights 2024-2029 What Key Findings Will Our Research Analysis Reveal? How big is the global ophthalmic implants market? What are the factors driving the global ophthalmic implants market growth? Which product type will dominate the global ophthalmic implants market growth? Which region will have the highest growth in the global ophthalmic implants market? Who are the major players in the global ophthalmic implants market? What is the growth rate of the global ophthalmic implants market? Why Arizton? 100% Customer Satisfaction 24x7 availability – we are always there when you need us 200+ Fortune 500 Companies trust Arizton's report 80% of our reports are exclusive and first in the industry 100% more data and analysis 1500+ reports published till date Post-Purchase Benefit 1hr of free analyst discussion 10% off on customization About Us: Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services. We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
